Antimicrobial Stewardship Program

Global funding has reached an all-time high but falls far short of what's needed to eliminate TB.

Though incidence is down, treatment success for resistant strains is low.

Safety profile was good, and sensitivity analysis favored delamanid as part of MDR-TB treatment.

TB remains high in many low- and middle-income nations, and about 558,000 people in 2017 developed rifampicin-resistant TB.

The changes prioritize newer medications and oral regimens over injectable drugs.

Commitments included scaling up research investments and building a framework for country accountability on steps to reach the declaration's goals.

Almost a third of TB cases in India are multidrug-resistant, and rates are climbing in Chinese kids.

Funds will help combat resistance, launch a TB surveillance center.

About 20% of TB cases globally are resistant, and 5% are resistant to both isoniazid and rifampicin.